• European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA• Launch preparations are underway to bring the second approved golimumab biosimilar to patients acro...
View DetailsGuangzhou,China– September 10, 2025 –Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and biosimilars, today announced that the MHRA hasapproved Qletli® (adalimumab), a bios...
Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
Guangzhou, China/Bad Vilbel, Germany –Bio-Thera will maintainresponsibility for development, manufacturing, and supply of the tocilizumabbiosimilar to Roche’s RoActemra® reference brand. STADA, including its affiliates, will have exclusive rights to ...
